Sex differences in toxicity and outcomes in patients with sarcoma treated in the perioperative setting at a comprehensive cancer center
Ilaria Tortorelli(Istituto Oncologico Veneto), Antonella Brunello(Istituto Oncologico Veneto), Marco Maruzzo(Istituto Oncologico Veneto), Chiara De Toni(Istituto Oncologico Veneto), Sara Lonardi(Istituto Oncologico Veneto), Fabio Murtas(University of Padua), Benedetta Chiusole(Istituto Oncologico Veneto), A. Banzato(Istituto Oncologico Veneto), Marina Coppola(Istituto Oncologico Veneto), Selma Ahcene Djaballah(Istituto Oncologico Veneto), Maital Bolshinsky(Istituto Oncologico Veneto), Umberto Basso(Istituto Oncologico Veneto), Salvatore Vizzaccaro(Istituto Oncologico Veneto), Antonella Galiano(Istituto Oncologico Veneto), Vittorina Zagonel(Istituto Oncologico Veneto)
Cited by 1
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k